Novo Holdings A S Makes New $6.08 Million Investment in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Novo Holdings A S bought a new position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 4,250,000 shares of the company's stock, valued at approximately $6,078,000. Novo Holdings A S owned approximately 3.44% of Mersana Therapeutics at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of MRSN. Wells Fargo & Company MN raised its stake in Mersana Therapeutics by 40.3% in the 4th quarter. Wells Fargo & Company MN now owns 67,483 shares of the company's stock worth $97,000 after acquiring an additional 19,368 shares during the last quarter. SG Americas Securities LLC grew its holdings in Mersana Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 112,291 shares of the company's stock valued at $161,000 after purchasing an additional 25,058 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Mersana Therapeutics during the 4th quarter worth approximately $37,000. Geode Capital Management LLC increased its holdings in Mersana Therapeutics by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,442,250 shares of the company's stock worth $3,493,000 after acquiring an additional 29,035 shares in the last quarter. Finally, MetLife Investment Management LLC raised its position in Mersana Therapeutics by 115.7% during the fourth quarter. MetLife Investment Management LLC now owns 73,150 shares of the company's stock worth $105,000 after acquiring an additional 39,234 shares during the period. 93.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MRSN. William Blair began coverage on shares of Mersana Therapeutics in a research note on Thursday, February 6th. They issued an "outperform" rating on the stock. Wedbush reissued an "outperform" rating and issued a $4.00 price objective on shares of Mersana Therapeutics in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $4.00.

Mersana Therapeutics Trading Down 8.2 %

Mersana Therapeutics stock traded down $0.03 during trading on Monday, reaching $0.37. 1,768,937 shares of the company were exchanged, compared to its average volume of 2,504,750. The stock's 50 day simple moving average is $0.40 and its two-hundred day simple moving average is $1.12. The company has a market capitalization of $45.49 million, a P/E ratio of -0.60 and a beta of 1.32. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. Mersana Therapeutics, Inc. has a 52-week low of $0.26 and a 52-week high of $3.63.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. The firm had revenue of $16.36 million during the quarter, compared to analyst estimates of $7.71 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. On average, equities research analysts expect that Mersana Therapeutics, Inc. will post -0.62 earnings per share for the current fiscal year.

Mersana Therapeutics Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.